| P2093 | author name string | Reinhold Vieth | |
| | H Richard Barthel | |
| P2860 | cites work | Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety | Q33610622 |
| | Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence? | Q33732423 |
| | Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. | Q34067652 |
| | Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol | Q34166759 |
| | Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women | Q34803344 |
| | [Benefits beyond the bones -- vitamin D against falls, cancer, hypertension and autoimmune diseases] | Q73069307 |
| | Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level | Q73396246 |
| | Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis | Q79088461 |
| P433 | issue | 4 | |
| P921 | main subject | glucocorticoid-induced osteoporosis | Q7611600 |
| | osteoporosis | Q165328 |
| | vitamin D | Q175621 |
| P304 | page(s) | 250-251 | |
| P577 | publication date | 2004-02-10 | |
| P1433 | published in | Rheumatology International | Q15763689 |
| P1476 | title | Lack of generalizable evidence of the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis: comment on the article by Ringe et al. | |
| P478 | volume | 24 | |